Table of Contents

State/Territory Name: California

State Plan Amendment (SPA) #: CA-22-0065

This file contains the following documents in the order listed:1) Approval Letter2) CMS 179 Form3) Approved SPA Pages

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-14-26 Baltimore, Maryland 21244-1850



<u>Center for Medicaid and CHIP Services</u> Disabled and Elderly Health Programs Group

01/03/2023

Jacey Cooper, Director Department of Health Care Services Attn: Director's Office P.O. Box 997413, MS 0000 Sacramento, CA 95899-7413

Dear Jacey Cooper:

The CMS Division of Pharmacy team has reviewed California's State Plan Amendment (SPA) 22-0065 received in the CMS Division of Program Operations on October 24, 2022. This SPA proposes to revise the Medi-Cal reimbursement rate for physician administered drugs such that it will continually align with the Medicare Part B Fee schedule reimbursement rate.

Based on the information provided and consistent with the regulations at 42 CFR 430.20, we are pleased to inform you that CA-22-0065 is approved with an effective date of October 1, 2022. We are attaching a copy of the signed CMS-179 form, as well as the pages approved for incorporation into California's state plan.

If you have any questions regarding this request, please contact Whitney Swears at 410-786-6543 or Whitney.Swears@cms.hhs.gov.

Sincerely,

Cynthia R. Digitally signed by Cynthia R. Denemark -S Denemark -S Date: 2023.01.04 14:07:23 -05'00'

Cynthia R. Denemark, R.Ph. Acting Director Division of Pharmacy DEHPG/CMCS/CMS

Cc: Angeli Lee, California Department of Health Care Services Erika Sky, California Department of Health Care Services Cheryl Young, CMS, Medicaid and CHIP Operations Group

CENTERS FOR MEDICARE & MEDICAID SERVICES	OMB No. 0938-0193
TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL	1. TRANSMITTAL NUMBER 2. STATE
	2 2 <u>0 0 6 5</u> CA
	3. PROGRAM IDENTIFICATION: TITLE OF THE SOCIAL
FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES	
	SECONTRACT () XIX () XXI
TO: CENTER DIRECTOR	4. PROPOSED EFFECTIVE DATE
CENTERS FOR MEDICAID & CHIP SERVICES	October 1, 2022
DEPARTMENT OF HEALTH AND HUMAN SERVICES	
5. FEDERAL STATUTE/REGULATION CITATION	6. FEDERAL BUDGET IMPACT (Amounts in WHOLE dollars)
Section 1847A(b)(8) of the Social Security Act (42 U.S.C. 1395w–3a(b)(8))	a FFY 2022-23 \$ 497,255 b FFY 2023-24 \$ 639,475
	·····
7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT	8. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable)
Supplement 2 to Attachment 4.19-B, page 10	Supplement 2 to Attachment 4.19-B, page 10
	Supplement 2 to Attachment 4.19-b, page 10
9. SUBJECT OF AMENDMENT	
Amends the Medi-Cal reimbursement rate for physician-administered	ed drugs (PAD) to refer to the Medicare Part B rate without the
specific definition of Average Sales Price (ASP) plus 6 percent. PA	
the particular product as published in the Medicare Physician Fee S	Schedule (MPFS) at the time the service is rendered.
10. GOVERNOR'S REVIEW (Check One)	
${igodoldoldoldoldoldoldoldoldoldoldoldoldol$	• OTHER, AS SPECIFIED:
O COMMENTS OF GOVERNOR'S OFFICE ENCLOSED	Please note: The Governor's Office does not wish to review
NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL	the State Plan Amendment.
	5. RETURN TO
	epartment of Health Care Services
	ttn: Director's Office
	.O. Box 997413, MS 0000 acramento, CA 95899-7413
13. TITLE	acramento, CA 35033-7415
State Medicaid Director	
14. DATE SUBMITTED	
October 24, 2022	
FOR CMS US	
	7. DATE APPROVED
	January 3, 2023
	CycNAFURE OF ARREVING OFFICIAL
October 1, 2022	Denemark -S Date: 2023.01.04 14:07:53 -05'00'
20. TYPED NAME OF APPROVING OFFICIAL	1. TITLE OF APPROVING OFFICIAL
Ormathia D. Danamanda D. Dh	
Cynthia R. Denemark, R.Ph.	Acting Director, Division of Pharmacy

Supplement 2 to Attachment 4.19-B Page 10

STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT STATE: CALIFORNIA

METHODS AND STANDARDS FOR ESTABLISHING PAYMENT RATES – PRESCRIBED DRUGS

PAYMENT METHODOLOGY FOR PHYSICIAN ADMINISTERED DRUGS

The reimbursement rate for physician administered drugs shall be equal to the Medicare Part B reimbursement rate for drugs and biologicals, when available for a particular product and published by CMS in the Medicare Fee Schedule (MFS), as described in Section 1847A of the Social Security Act.

When a Medicare Part B reimbursement rate is not available or published by CMS for a physician administered drug, the reimbursement rate will be determined as follows:

- If based on a National Drug Code (NDC), the NDC rate of reimbursement shall be equal to the drug's ingredient cost, as described in Paragraph 4 of this supplement, or
- If based on a Healthcare Common Procedure Coding system (HCPCS) code, the HCPCS code rate of reimbursement shall be equal to the volume-weighted average of the drug's ingredient cost for generically equivalent drugs as described in Paragraph 4 of this supplement.

For physician administered drugs purchased pursuant to the 340B program, a covered entity is required to bill and will be reimbursed an amount not to exceed the entity's actual acquisition cost for the drug, as charged by the manufacturer at a price consistent with Section 256b of Title 42 of the United States Code.